Click the
button to view the videos in full screen
Influenza A (H1N1) Virus: Are We Ready?
LAURENE MASCOLA, M.D.
CHIEF, ACUTE COMMUNICABLE DISEASE CONTROL PROGRAM
LA COUNTY DEPARTMENT OF PUBLIC HEALTH
MODERATOR: PAOLA TEMPESTI, M.D.; CHAIR, INFECTION PREVENTION COMMITTEE
FACULTY DISCLOSURE: According to CMA guidelines for faculty disclosure of commercial support, we are required to announce the following:
Dr. Mascola states she is on the Speakers Bureau for Merck and Medimmune and consultant to the infectious disease board of Merck.
OBJECTIVES
At the end of the presentation, attendees will be able to: - identify current H1N1 “hot spots” in LA County and who is at risk for H1N1 influenza.
- recognize the signs and symptoms of HiN1.
- cite the ecommended treatment and prophylaxis modalities for H1N1and recommended infection prevention measures
- cite the roles of local, state, and federal agencies in responding to an H1N1 outbreak.
- know what to do if you suspect H1N1.
- identifycultural/linguistic factors that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of H1N1 influenza
|
|
9/15/2009
|
|
Laurene
Mascola,
MD.
|
|
Presenter
|
|
Hope Conference Center
|
|
|
|
|
Preconception Counseling: An Underutilized Resource
|
|
MARC INCERPI, M.D.
DEPARTMENT OF OB/GYN, PSJMC
MODERATOR: AUNG THWIN, M.D.; CHAIRMAN, OB/GYN DEPARTMENT, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following:
Dr. Incerpi states he has nothing to disclose.
Dr. Thwin states he has nothing to disclose.
OBJECTIVES
At the end of the presentation, attendees will be able to: - define preconception counseling
- discuss the goals of preconception counseling
- isolate some of the barriers to preconception counseling and overcome them
- implement strategies for preconception counseling
- reduce the disparities in adverse pregnancy outcomes
|
|
|
|
Learning Disabilities and Vision
|
|
WALTER FIERSON, M.D.
CLINICAL ASSISTANT PROFESSOR, DEPARTMENT OF OPHTHALMOLOGY
KECK SCHOOL OF MEDICINE, USC
MODERATOR: Sheldon Kishineff, M.D.; Pediatric Liaison, Medical Education Committee
FACULTY DISCLOSURE: According to CMA guidelines for faculty and planner disclosure of commercial support, we are required to announce the following:
Dr. Fierson states he has nothing to disclose.
Dr. Kishineff states he has nothing to disclose.
OBJECTIVES
At the end of the presentation, attendees will be able to: - • define learning disabilities and dyslexia and distinguish them from other forms of developmental disability.
- • discuss the pathophysiology of learning disabilities and dyslexia in modern neurological terms, and describe how they should and should not be treated
- • appropriately advise parents who are asking for advice on the subject
- • identify cultural/linguistic factors that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of learning disabilities and dyslexia.
|
|
|
|
Current Approach to the Diagnosis the Management of Lupus
|
|
BEVRA HAHN, M.D.
PROFESSOR OF MEDICINE; CHIEF, DIVISION OF RHEUMATOLOGY; DEPT. OF MEDICINE
DAVID GEFFEN SCHOOL OF MEDICINE, UCLA MODERATOR: PENG FAN, M.D.; MEMBER, MEDICAL EDUCATION COMMITTEE, PSJMC
FACULTY DISCLOSURE:According to CMA guidelines for faculty disclosure of commercial support, we are required to announce the following:
Dr. Hahn states she is a consultant for Biogen IDEC, Bristol Myers Squibb and Idera Pharmaceuticals, is a grant recipient from Aspreva, and is on the Data Safety Monitoring Board for Bristol Myers Squibb.
OBJECTIVES
At the end of the presentation, attendees will be able to: - discuss current thoughts regarding pathogenesis of SLE
- recognize the signs and symptoms of SLE, conduct an appropriate work-up, and make the diagnosis
- incorporate current therapeutic approaches to SLE
- identify cultural/linguistic factors that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of SLE
|
|
|
|
|
|
Osteoporosis Update: An Orthopedist's Perspective
|
|
JOHN KAUFMAN, M.D.
SECTION EDITOR, ORTHOPEDICS TODAY
MODERATOR: JEFFERY KORCHEK, M.D., ORTHOPEDIC SECTION, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty disclosure of commercial support, we are required to announce the following:
Dr. Kaufman states he is on the Speakers Bureau for Novartis, Pfizer, and Merck and is a consultant for Amgen. His presentation was reviewed ahead of time to identify and resolve any conflicts of interest.
OBJECTIVES: At the end of the presentation, attendees will be able to:- determine who is at risk for bone density loss.
- differentiate between normal bone density, osteopenia and osteoporosis.
- incorporate current guidelines for prevention and treatment of bone density loss into practice.
- identify cultural/linguistic factors that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of bone density loss.
|
|
|
|
|